DOCSLIB.ORG

PROCLAMATION 7207-^ULY 1, 1999 113 STAT. 2105 to Extend Nondiscriminatory Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PROCLAMATION 7207-^ULY 1, 1999 113 STAT. 2105 to Extend Nondiscriminatory Treatment PROCLAMATION 7207-^ULY 1, 1999 113 STAT. 2105 Proclamation 7207 of July 1,1999 To Extend Nondiscriminatory Treatment (Normal Trade Relations Treatment) to Products of Mongolia and To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates By the President of the United States of America A Proclamation 1. The United States has had in effect a bilateral Agreement on Trade Relations with Mongolia since 1991 and has provided normal trade re­ lations treatment to the products of Mongolia since that time. I have found Mongolia to be in full compliance with the freedom of emigra­ tion requirements of title IV of the Trade Act of 1974 (the "Trade Act") (19 U.S.C. 2432). 2. Pursuant to section 2424(b)(1) of Public Law 106-36, and having due regard for the findings of the Congress in section 2424(a) of said Law, I hereby determine that title IV of the Trade Act (19 U.S.C. 2431-2441) should no longer apply to Mongolia. 3. On November 13, 1998, members of the World Trade Organization (WTO), including the United States and 21 other major trading coun­ tries, announced in the WTO an agreement to eliminate tariffs on cer­ tain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination negotiations during the Uruguay Round of Multilateral Trade Negotiations (the "Uruguay Round"). A similar agreement between the United States and 16 other major trading coun­ tries eliminating tariffs on enumerated pharmaceuticals and chemical intermediates was implemented for the United States on April 1, 1997, by Proclamation 6982, adding such goods to the scope of the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and reflected in Schedule XX-United States of America, an­ nexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (1994) (Schedule XX). 4. Section 111(b) of the Uruguay Roimd Agreements Act (URAA) (19 U.S.C. 3521(b)) authorizes the President to proclaim the modification of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Roimd, if the United States agrees to such action in a multilateral negotiation under the auspices of the WTO, and after compliance with the consultation and layover require­ ments of section 115 of the URAA (19 U.S.C. 3524). Section 111(b) also authorizes the President to proclaim such modifications as are nec­ essary to reflect such duty treatment in Schedule XX by means of rec­ tifications thereof. 5. On April 29, 1999, pursuant to section 115 of the URAA, the United States Trade Representative (USTR) submitted a report to the Com­ mittee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate ("the Committees") that sets forth the proposed tariff eliminations, together with the advice received from the appropriate private sector advisory committee and the United States International Trade Commission regarding the proposed tariff 113 STAT. 2106 PROCLAMATION 7207^JULY 1, 1999 eliminations. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed actions. 6. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), author­ izes the President to embody in the Harmonized Tariff Schedule of the United States (HTS) the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions there­ under, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction. 7. Pursuant to section 111(b) of the URAA, I have determined that Schedule XX should be modified to reflect the implementation by the United States of the multilateral agreement on certain pharmaceuticals and chemical intermediates negotiated rmder the auspices of the WTO. In addition, I have determined that the pharmaceuticals appendix to the HTS should be modified to reflect the duty eliminations provided in such agreement, and to make certain minor technical corrections in the identification of particular products in order to ensure that prod­ ucts are accorded the intended duty treatment. NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting vmder the authority vested in me by the Con­ stitution and the laws of the United States, including but not limited to section 2424(b)(2) of Public Law 106-36, section 111(b) of the URAA, and section 604 of the Trade Act, do hereby proclaim that: (1) Nondiscriminatory treatment (normal trade relations treatment) shall be extended to the products of MongoUa, which shall no longer be subject to title IV of the Trade Act. (2) The extension of nondiscriminatory treatment to the products of MongoUa shall be effective as of the date of signature of this proclama­ tion. (3) In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharma­ ceutical products and chemical intermediates, and to make technical corrections in the tariff treatment accorded to such products, the HTS is modified as set forth in the Annex to this proclamation. (4) Such modifications to the HTS shall be effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after the dates set forth in the Annex for the respective actions taken. (5) Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are su­ perseded to the extent of such inconsistency. IN WITNESS WHEREOF, I have hereimto set my hand this first day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-third. WILLIAM J. CLINTON PROCLAMATION 7207-JULY 1, 1999 113 STAT. 2107 ANNEX MODIFICATIONS TO THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES The Hannonized Tariff Schedule of the United States (HTS) U modified as provided herein, effective on the dates set forth for each annex section. Section A. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or tafte r July 1. 1999. the followinn products lire to be accorded dutv- free treatment: 1. For subheading^ s 290S.5.22.50.2910.30.00.2921.43.40: , 2922.19.20.2924.29.0S.wd 2933.39.20 the Rites of Du^ 1-Specul subcolunm is modined by insetting, in ilplnbetical order, the symbol "K" m the parentheses following the "Free" rate of duty in stich subcolumn tor each sudi subboding. 2. The Pharmaceutical Appendix to the HTS is modified as provided below: M. TiMe I of the Appendix is modified by adding the following new INN::, in alphabetical order, in the "noduct" column and theji- CAS numbers m the "CAS No." column: Product CAS Number 136470-7»4 eperezolid 163800-04-4 128638-7M 107724-20-9 1S36S2-3S-7 148031-34-9 15422S-1M 12354»4e-1 129300-27-2 aumiialaliiia 13S112-7»-2 bndofloxacin 164130-994 •wiofloKacin 157182-32-6 ianlimomab 167S16-91-3 alnartrw 154541-72-7 fasidatril 13S038-37-2 ahnoMplan 15432M7-6 ftscracetHn li093S-19-3 •knuiWa 61136-12-7 fehnzumab 167747-20-8 123013-22-8 12236448-7 fexofenadine 83799-24-0 13S00M<M fidarestat 136087-83-9 fUaminast 1411I4-34-I l5n2-124 flibamciiB 1679334)7-3 woiywMi 13814»07-8 foUHropin beta 1S0490-S4-9 aMtlpW* 183242-4I2-5 imdvitiea 144243-32-3 153206-464 143216-43-9 123018-47-3 Ibrapafnit 136468-36-3 136637-464 •IMaton 10691M7-0 138747-02-3 154365-76-7 13189-98-3 •vjBiadI 40077-87-4 fiilvestmt 129433-61-8 avMplan 15114046-4 Autnine 14299646-3 avoraln 140703-49-7 gagrdidine 6SI34-81-6 avdafmln 182212-66-4 gIMBOiODe 38398-n-2 13577ft62-7 galifloxacm 160738-37-8 baaaSnib 17904546-4 165101-61-9 gavcstind 133436-22-7 158318434 134143-28-3 156862-51-0 lide 132682-98-5 13682840-2 crosftimaril 142261-03-8 125802-71-3 139634-47-6 15Mg7-46-1 icopezil 143508-78-7 1WM7-94-1 igovonab 171636-30-1 132810-10-7 150378-17-9 17186641-7 indintvir 13888042-7 141549-75-9 177563-404 inHjxjniab 170277-31-3 159138-804 msuliB aipait 116094-23-6 iasoUn ghnhie 160337-93-1 136821-64-4 iMerftma aohnio-l 118390-30-0 121104-864 ioG«didicacidll23l) .74153-17,7 15077»494 ioflupane(l23l) 155798-07-5 136794-86-0 157238-324 iaiiMtopaM(l2}I) ig72SM)64 ipamoRlia 170851-704 17707V«(4 iroplact 154248-96-1 142155-434 urapafapt 117279^73-9 182912-684 jvswadinf 1559744)0-8 1864»-2»4 I7472^304 davudnt 163252-364 137476-77-2 182815-434 13^24^30•3 118976-384 170566-84-4 120958404 83513-484 175385-62-3 iei7SM04 1134574)5.9 153438494 tefiadafibtn I49S03-79L-7 891-60-1 IcvocclMz I300IS-77-8 140881-97-8 levoMlbal 14334»48-1 343914)4-3 UcMliiiel 133304-81-3 iaomS-4 159776-684 M1626460 1658004)3.3 diOMnavir 139910464 iuuiliipt 136381-8S-6 dutMlctide 1646S6-23-9 166089-32-3 162301-<H-S 145414-12-6 IS6St<-t9-9 110143-10-7 IS4S9I-S2-4 171049-14-2 I43664-1I-3 82186-77-4 141993-704 149tSM04) I43322-S8-1 164178-54-5 162706-37-1 159776-70-2 156001-11-2 134865-33-1 142298-004 mc^toaae(IIC) 94153-50-1 cniluneil 59989-IS-3 13838448-6 cnlimoiBab pc^ol l69802-<44> 141725-10-2 I3S773-S94 139886-32-1 113 STAT. 2108 PROCLAMATION 7207—JULY 1, 1999 Annex (con.) -2- Section A (con.) 2.
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Wo 2007/128674 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 November 2007 (15.11.2007) PCT WO 2007/128674 A2 (51) International Patent Classification: Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cor- A61K 31/00 (2006.01) A61K 31/551 (2006.01) nelis G. [NL/NL]; c/o SOLVAY PHARMACEUTICALS A61K 31/439 (2006.01) A61P 25/18 (2006.01) B.V., IPSI Department, CJ. Van Houtenlaan 36, NL-1381 A61K 31/4439 (2006.01) CP Weesp (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; Octrooibureau Zoan B.V., PCT/EP2007/053934 NL-1380 AC Weesp (NL). (22) International Filing Date: 23 April 2007 (23.04.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (25) Filing Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (26) Publication Language: English IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (30) Priority Data: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 061 13476.3 4 May 2006 (04.05.2006) EP RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, 60/797,355 4 May 2006 (04.05.2006) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): SOLVAY (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS B.V.
    [Show full text]
  • WO 2012/044761 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . 5 April 2012 (05.04.2012) WO 2012/044761 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US201 1/053876 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 29 September 201 1 (29.09.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Langi English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 12/893,344 29 September 2010 (29.09.2010) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNI¬ kind of regional protection available): ARIPO (BW, GH, VERSITY OF NORTH CAROLINA AT WILMING¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, TON [US/US]; 601 South College Road, Wilmington, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, NC 28403 (US).
    [Show full text]
  • Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing
    Allergy Asthma Immunol Res. 2019 Jan;11(1):e18 https://doi.org/10.4168/aair.2019.11.e18 pISSN 2092-7355·eISSN 2092-7363 Original Article Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2 Jae-Hyun Lee,1,2 Jung-Won Park1,2* 1Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea Received: Aug 6, 2018 ABSTRACT Revised: Sep 10, 2018 Accepted: Sep 22, 2018 Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing Correspondence to muscle spasm and pain. For more effective pain control, eperisone is usually prescribed Jung-Won Park, MD, PhD together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may Division of Allergy and Immunology, have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed Department of Internal Medicine, Yonsei to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate University College of Medicine, 50-1 Yonsei-ro, diagnostic approach for eperisone-induced anaphylaxis. Seodaemun-gu, Seoul 03722, Korea. Tel: +82- 2-2228-1961; Fax: +82-2-393-6884; Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug E-mail: [email protected] Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, Copyright © 2019 The Korean Academy of outcomes, and re-exposure information were analyzed.
    [Show full text]
  • Alzheimer's Disease Clinical Trials
    Clinical Trial Perspective 5 Clinical Trial Perspective Alzheimer’s disease clinical trials: past failures and future opportunities Clin. Invest. (Lond.) Over a decade has elapsed since the US FDA has approved a medication for Alzheimer’s Roy Yaari*,1,2 & Ann Hake1,2 disease (AD) despite clinical trials of numerous agents over a wide array of mechanisms 1Eli Lilly & Company, Lilly Corporate including neurotransmitter modulation and disease modifying therapy targeting Center, Indianapolis, IN 46285, USA 2Indiana University School of Medicine, amyloid and tau. The failures of clinical trials in AD may be due to inadequate Department of Neurology, Indianapolis, understanding of mechanisms of action and/or poor target engagement; however, IN 46202, USA other factors could include inadequate study design, stage of AD along the continuum *Author for correspondence: studied, inclusion of participants without Alzheimer’s pathology into clinical trials Tel.: +1 317 651 6163 and limited power of endpoint measures. Future studies will need to carefully assess [email protected] these possible shortcomings in design of upcoming trials, especially as the field moves toward studies of disease modifying agents (as opposed to symptomatic treatment) of AD and to patients that are very early in the disease spectrum. Keywords: Alzheimer’s disease • Alzheimer’s disease biomarkers • amyloid • clinical trials • preclinical Alzheimer’s disease • tau US FDA approved medications continue to provide significant, but modest More than three decades ago, the choliner- symptomatic benefit[5–7] . gic hypothesis proposed that degeneration The compound memantine introduced a of cholinergic neurons in the basal fore- second mechanism for symptomatic treat- brain and the associated loss of cholinergic ment of AD into clinical practice.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Sándor Farkas, MD
    ANALYSIS OF PHARMACODYNAMICS OF TOLPERISONE-TYPE CENTRALLY ACTING MUSCLE RELAXANTS IN NON-CLINICAL STUDIES AND RESEARCH INTO PRECLINICAL MODELLING OF MIGRAINE Dissertation for the degree of Doctor of Philosophy (PhD) Sándor Farkas, MD Doctoral School of Pharmaceutical Sciences Neuropharmacology Programme Doctoral School Leader: Prof. Dr. Erika Pintér Programme Leader: Prof. Dr. Erika Pintér Supervisor: Prof. Dr. Zsuzsanna Helyes Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs Pécs, 2016 Table of contents 1 Chapter 1: Pharmacodynamics of tolperisone-type centrally acting muscle relaxants .............. 3 1.1 Introduction .............................................................................................................................. 3 1.1.1 General objectives ............................................................................................................ 3 1.1.2 Specific objectives of the studies ..................................................................................... 3 1.2 Methods ................................................................................................................................... 4 1.2.1 Neuropharmacological studies on efficacy and side effects in mice ............................... 4 1.2.2 Instrumental neurophysiological studies in unconscious cats ......................................... 6 1.2.3 Instrumental neurophysiological studies in unconscious rats ......................................... 7 1.2.4 Studies in the isolated
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]